Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans

TLR8 agonists have the potential for use as immunomodulatory components in therapeutic modalities for viral infections such as chronic HBV (CHB) and HIV. In this study, using peripheral blood samples from a phase 1a clinical trial, we examined the acute effects of a single oral administration of a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayithan, Natarajan, Ghosh, Alip, Dwivedi, Ankit, Wallin, Jeffrey J., Tan, Susanna K., Chen, Diana, Kottilil, Shyam, Poonia, Bhawna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706304/
https://www.ncbi.nlm.nih.gov/pubmed/34960669
http://dx.doi.org/10.3390/v13122400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706304/
https://www.ncbi.nlm.nih.gov/pubmed/34960669
http://dx.doi.org/10.3390/v13122400

Ejemplares similares